Literature DB >> 10913359

Accessibility of the high-mannose glycans of glycoprotein gp120 from human immunodeficiency virus type 1 probed by in vitro interaction with mannose-binding lectins.

C H Astoul1, W J Peumans, E J Van Damme.   

Abstract

The direct interaction of mannose-specific plant lectins with gp120 of HIV-1 was studied by surface plasmon resonance. Inhibition experiments indicated that exposed high mannose type glycans play a key role in the interaction. Most of the lectins specifically accommodate outer alpha1,2-, alpha1,3-, or alpha1,6-linked di- or trimannosides, and especially legume lectins, also interact with the trimannoside core of the complex type glycans. The unexpected affinity of some lectins towards gp120 presumably results from conformational differences in their binding sites. These results demonstrate that mannose-specific plant lectins are powerful tools to study the accessibility and elucidate the function of the gp120 glycans in the recognition and infection of the host cells by HIV-1. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913359     DOI: 10.1006/bbrc.2000.3166

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

Authors:  Jan Balzarini; Sigrid Hatse; Kurt Vermeire; Katrien Princen; Stefano Aquaro; Carlo-Federico Perno; Erik De Clercq; Herman Egberink; Guy Vanden Mooter; Willy Peumans; Els Van Damme; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4.

Authors:  Karolin Hijazi; Yufei Wang; Carlo Scala; Simon Jeffs; Colin Longstaff; Daniel Stieh; Beth Haggarty; Guido Vanham; Dominique Schols; Jan Balzarini; Ian M Jones; James Hoxie; Robin Shattock; Charles G Kelly
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.